Aptahem’s CEO interviewed during the Biotechgate conference
Mikael Lindstam, CEO at Aptahem, was interviewed during the Biotechgate digital partnering conference. In the video he describes the development process with the company’s lead candidate Apta-1, from discovery, through manufacturing and preclinical studies up to clinical phase. The interview also explains why Apta-1 is thought to be a potential drug candidate for sepsis.
Watch the interview with Aptahem's CEO Mikael Lindstam by following the link below:
For further information:
Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
E-mail: ml@aptahem.com
About Aptahem
Aptahem AB (APTA) is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company’s primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in sepsis patients, among others. The company possesses patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.
Tags: